Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform.
The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic surgeon to manage all aspects of suture use and needle disposal without the need for an assistant, according to the Madison, N.J.-based company.
Origami Surgical’s newly cleared absorbable and non-absorbable sutures were designed based on input from surgeons who perform robotic hernia, prostate and bariatric procedures. The company previously launched StitchKit PTFE devices for robotic-assisted sacrocolpopexy and rectopexy procedures. In November 2020, the company began marketing StitchKit PARK, which enables the surgeon to customize the StitchKit device’s contents with the sutures of their choice.
“We are excited to grow our StitchKit portfolio and promote the benefits of safety, autonomy and efficiency for new robotic procedures,” said company CEO Sean McNerney in a news release.